8 March 2021 - COVID-19 testing
Shares in AIM-listed Avacta have hit a new high following the announcement that its rapid antigen lateral flow test can detect the dominant new variants of coronavirus, as well as the original strain. These include the B117 or Kent strain, which is prevalent in the UK, but which has now also been found in over 50 countries. This is further good news for the company and the shares remain a BUY
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
